Announcements Trials

Browse Landscape

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 2 Neoplasms 2 Triple Negative Breast Neoplasms 1 Neoplasm Metastasis 1 Glioma 1 Carcinosarcoma 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

Temozolomide 41 Radiotherapy 15 Magnetic Resonance Spectroscopy 12 Surgical Procedures, Operative 10 Bevacizumab 10 Irinotecan 9 Radiation 8 Nivolumab 7 Carmustine 7 Specimen Handling 6 Radiosurgery 6 Carboplatin 6 ribociclib 5 O(6)-benzylguanine 5 Imiquimod 5 IL13-PE38 5 Flucytosine 5 Filgrastim 5 Erlotinib Hydrochloride 5 Cyclophosphamide 5 Aminolevulinic Acid 5 vandetanib 4 sargramostim 4 Topotecan 4 Imatinib Mesylate 4 Etoposide 4 Craniotomy 4 vocimagene amiretrorepvec 3 temsirolimus 3 lentiviral minigene vaccine of COVID-19 coronavirus 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Glioma × LY-2157299 × Clear all

NCT01682187 2024-11-07

A Dose-Escalation Study in Participants With Recurrent Malignant Glioma

Eli Lilly and Company

Phase 1 Completed

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡